mRNA-4157 Plus Pembrolizumab Continues to Improve RFS in High-Risk Melanoma
Source: Targeted oncology, December 2023
Findings from 3-year follow-up of KEYNOTE-942/mRNA-4157-P201 show that the cancer vaccine mRNA-4157 plus pembrolizumab reduced the risk of recurrence or death in patients with stage III/IV melanoma following resection.
Planned 3-year follow-up of the KEYNOTE-942/mRNA-4157-P201 study (NCT03897881) evaluating adjuvant treatment of mRNA-4157 (V940), an investigational cancer vaccine, plus pembrolizumab (Keytruda) found that the combination continued to confer a clinically meaningful benefit in recurrence-free survival (RFS) and reduced the risk of recurrence or death by 49% (HR, 0.501; 95% CI, 0.288-0.906; one-side nominal P =.0095) in patients with stage III/IV high-risk melanoma who underwent complete resection.
The combination also continued to improve distant metastasis-free survival (DMFS) and reduced the risk of distant metastasis or death by 62% (HR, 0.384; 95% CI, 0.172-0.858, one-sided nominal P =.0077) compared with pembrolizumab alone.